Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06029439 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Safety and Effectiveness of NMRA-335140-501

A Phase 3 study of Major Depressive Disorder, sponsored by Neumora Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
1,000
Enrollment target
20
Study locations

NCT06029439 is a Phase 3 study of Major Depressive Disorder that is actively recruiting participants, run by Neumora Therapeutics. The registered enrollment target is 1,000 participants, above the 373-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (168% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06029439, a Phase 3 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Neumora Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.

Conditions Studied

Major Depressive Disorder

Interventions

  • DRUG NMRA-335140

Study Locations (20)

California

  • Neumora Investigator site - Bellflower
  • Neumora Investigator Site - Cerritos
  • Neumora Investigator Site - Encino
  • Neumora Investigator Site - Garden Grove
  • Neumora Investigator Site - Glendale
  • Neumora Investigator Site - Imperial
  • Neumora Investigator Site - Irvine
  • Neumora Investigator Site - Lafayette
  • Neumora Investigator Site #1 - Long Beach
  • Neumora Investigator site - Long Beach
  • Neumora Investigator Site - Los Angeles
  • Neumora Investigator Site - Newport Beach
  • Neumora Investigator Site - Oceanside
  • Neumora Investigator Site #1 - Orange

Arkansas

  • Neumora Investigator Site - Bentonville
  • Neumora Investigator Site #1 - Little Rock
  • Neumora Investigator site - Little Rock
  • Neumora Investigator Site - Rogers

Alabama

  • Neumora Investigator site - Huntsville

Arizona

  • Neumora Investigator Site - Phoenix

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-11-10
Est. Completion 2027-06
Phase Phase 3

Sponsor

Neumora Therapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06029439

The ClinicalTrials.gov registry entry for NCT06029439 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 373-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (168% higher). The listed sponsor is Neumora Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which NMRA-335140 is the first listed.

NCT06029439 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Alabama.

Frequently Asked Questions

What is clinical trial NCT06029439 about?

NCT06029439 is a clinical study titled "Study to Assess the Safety and Effectiveness of NMRA-335140-501". This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD...

What is the current status of trial NCT06029439?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2023-11-10. Estimated completion is 2027-06.

What conditions does trial NCT06029439 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT06029439?

The interventions under investigation include: NMRA-335140 (DRUG).

Who is sponsoring clinical trial NCT06029439?

This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06029439 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.